hydroxychloroquine has been researched along with Renal Insufficiency in 10 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloroquine and hydroxychloroquine are quinoline derivatives used to treat malaria." | 5.05 | Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. ( Cook, J; Joshi, A; Nicol, MR; Rizk, ML; Sabato, PE; Savic, RM; Wesche, D; Zheng, JH, 2020) |
| "Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases including systemic lupus, rheumatoid arthritis, sarcoidosis, and Sjogren syndrome; cutaneous disorders, antiphospholipid syndrome, and have recently been employed at higher dioses in oncology." | 2.58 | Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. ( Abdulaziz, N; McCune, WJ; Shah, AR, 2018) |
| "Reduction of the hydroxychloroquine (HCQ) dosage is recommended in systemic lupus erythematosus (SLE) patients with renal impairment, but a pharmacokinetics (PK) study of patients with renal impairment has not yet been performed." | 1.91 | Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment. ( Furudate, S; Hashiguchi, M; Nagai, Y; Ohshima, M; Setoguchi, K; Shimada, K; Shimizu, M; Yokogawa, N, 2023) |
| "To evaluate the association and dose-response pattern between antimalarial drugs and overall and cause specific mortality in SLE patients." | 1.62 | Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. ( Da, Z; Ding, X; Feng, X; Hu, H; Jin, Z; Li, J; Liu, L; Pan, W; Qian, X; Sun, L; Tan, J; Tao, J; Wang, F; Wang, M; Wei, H; Wu, J; Wu, M; Zhang, M; Zou, Y, 2021) |
| " This position statement recommends dosage adjustment for these drugs in the context of renal impairment." | 1.56 | Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function. ( Andreoli, MCC; Bastos, K; D'Avila, R; Kraychete, A; Misael, AM; Moura-Neto, JA; Nascimento, MMD; Silva, DRD, 2020) |
| "Prednisone was used at a starting dose from about 0." | 1.33 | Muscle involvement in sarcoidosis: a retrospective and followup studies. ( Bardin, T; Berenbaum, F; Fayad, F; Lioté, F; Orcel, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimizu, M | 1 |
| Furudate, S | 1 |
| Nagai, Y | 1 |
| Shimada, K | 1 |
| Ohshima, M | 1 |
| Setoguchi, K | 1 |
| Hashiguchi, M | 1 |
| Yokogawa, N | 1 |
| Defoort-Dhellemmes, S | 1 |
| Dos Reis Neto, ET | 1 |
| Kakehasi, AM | 1 |
| de Medeiros Pinheiro, M | 1 |
| Ferreira, GA | 1 |
| Marques, CDL | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| Sato, EI | 1 |
| Reis, APMG | 1 |
| Xavier, RM | 1 |
| Provenza, JR | 1 |
| Nicol, MR | 1 |
| Joshi, A | 1 |
| Rizk, ML | 1 |
| Sabato, PE | 1 |
| Savic, RM | 1 |
| Wesche, D | 1 |
| Zheng, JH | 1 |
| Cook, J | 1 |
| Moura-Neto, JA | 1 |
| Misael, AM | 1 |
| Silva, DRD | 1 |
| D'Avila, R | 1 |
| Andreoli, MCC | 1 |
| Kraychete, A | 1 |
| Bastos, K | 1 |
| Nascimento, MMD | 1 |
| Jin, Z | 1 |
| Wang, F | 1 |
| Pan, W | 1 |
| Liu, L | 1 |
| Wu, M | 1 |
| Hu, H | 1 |
| Ding, X | 1 |
| Wei, H | 1 |
| Zou, Y | 1 |
| Qian, X | 1 |
| Wang, M | 1 |
| Wu, J | 1 |
| Tao, J | 1 |
| Tan, J | 1 |
| Da, Z | 1 |
| Zhang, M | 1 |
| Li, J | 1 |
| Feng, X | 1 |
| Sun, L | 1 |
| Abdulaziz, N | 1 |
| Shah, AR | 1 |
| McCune, WJ | 1 |
| Ekwom, PE | 1 |
| Fayad, F | 1 |
| Lioté, F | 1 |
| Berenbaum, F | 1 |
| Orcel, P | 1 |
| Bardin, T | 1 |
| Contreras Blasco, MA | 1 |
4 reviews available for hydroxychloroquine and Renal Insufficiency
| Article | Year |
|---|---|
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
Topics: Age Factors; Aging; Antiviral Agents; Chloroquine; Clinical Trials, Phase II as Topic; Clinical Tria | 2020 |
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administ | 2018 |
[Erosive or inflammatory osteoarthritis: the great unknown].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Psoriatic; Diagnosis, Differential; Finge | 2007 |
6 other studies available for hydroxychloroquine and Renal Insufficiency
| Article | Year |
|---|---|
Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment.
Topics: Antirheumatic Agents; East Asian People; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; | 2023 |
[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
Topics: Antimalarials; Betacoronavirus; Bone Density Conservation Agents; Contraindications, Drug; Coronavir | 2020 |
Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.
Topics: Antimalarials; Brazil; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Human | 2020 |
Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
Topics: Adult; Antimalarials; China; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxyc | 2021 |
Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Arthritis; Black People; Child; Data Collection; Diabete | 2013 |
Muscle involvement in sarcoidosis: a retrospective and followup studies.
Topics: Adult; Cardiomyopathies; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studie | 2006 |